Introduction
Transforming growth factor b (TGF-b) is a potent regulator of tumor growth, with an inhibitory effect at the first stage of tumorigenesis but a stimulating effect on tumor growth at the later stage of cancer [1] [2] [3] . TGF-b intracellular signaling is initiated by activation of the specific TGF-b transmembrane receptors type I and type II, which form a complex. Activation of the serine/threonine kinases of TGF-b receptors is essential for propagation of the signal, and it has been shown that the type I receptor (TbR-I) acts downstream of the type II receptor (TbR-II) [1] [2] [3] . TbR-I phosphorylates Smad2 and Smad3 proteins, which are important components of TGF-b intracellular signaling. Phosphorylation of ShcA [4] and endoglin [5] by TGF-b receptors has also been reported. No other substrates of TbR-I have been explored, although it is unlikely that TbR-I would phosphorylate only four proteins. Recent studies have suggested that other kinases may have a significant number of substrates. For example, 181 substrates were identified for Cdk1 [6] and 175 substrates for casein kinase 2 [7] , showing a multiplicity of pathways regulated by these kinases. Thus, a search for substrates of TbR-I may unveil novel mechanisms in TGF-b signaling. Because the interaction between a kinase and its substrate is transient, special types of screening techniques must be used [8] . Here we describe a screen for novel substrates of TbR-I using a protein expression library and identify eukaryotic elongation factor 1A1 (eEF1A1) as a novel substrate of TbR-I.
Protein synthesis is one of the fundamental processes in cells. It involves more than a hundred different proteins and is subject to tight regulation. Control of protein synthesis at the elongation phase of translation is important for cell proliferation and apoptosis, and deregulated protein synthesis may result in carcinogenic transformation of cells [9] . Among proteins directly regulated by and/or interacting with TGF-b receptors, TRIP-1 and eIF2a have been identified [10] [11] [12] . TRIP-1 has a homology to a component of the eIF3 complex, although TRIP-1's role in TGF-b signaling was claimed not to be linked to the regulation of mRNA translation [11] . eIF2a has also been explored as a component of the TGF-b/Smad transcriptional pathway [12] . TGF-b-dependent regulation of protein synthesis has been approached by studies of the mTOR pathway and p70 S6 kinase [13, 14] . However, a direct TGF-b receptor-protein synthesis link, similar to the receptor-Smad2/3 link to transcriptional regulation, has not been reported. Here we show that TbR-I phosphorylates eEF1A1 at Ser300 and that Ser300 is important for efficient mRNA translation. We also demonstrate that the phosphorylation status of Ser300 in eEF1A1 is important for cell proliferation and contributes to the TGF-b-dependent inhibition of cell growth. Deregulated expression of eEF1A has been observed in breast, colorectal, and prostate cancers [9, 15] . We show also that the phosphorylation of Ser300 is decreased in human breast tumor cells as compared to epithelial cells in noncancerous cases, therefore supporting functional importance of Ser300 phosphorylation in cancer.
Results eEF1A1 Is a Substrate of TbR-I Kinase
To identify novel substrates of TbR-I, we screened a human fetal lung lgt11 phage library with purified TbR-I containing constitutively active kinase. The cytoplasmic domain of human TbR-I with a Thr204Asp mutation fused to glutathione S-transferase (GST) was purified as described previously [16] . The Thr204Asp mutation leads to constitutive activation of the TbR-I kinase. The functional similarity of the TbR-I Thr204Asp mutant with the wild-type receptor has been confirmed previously [16] . To confirm that the substrate specificity of the GST-TbR-I Thr204Asp construct was preserved, we showed that GST-TbR-I Thr204Asp phosphorylated GSTSmad2 but not GST-Smad1, as reported previously [16, 17] .
The specificity of GST-TbR-I Thr204Asp was also proven by the phosphorylation of the C-terminal serine residues in Smad3 and Smad2: these serine residues are specific phosphorylation sites for TbR-I [16] .
A number of phage clones were found to be specifically phosphorylated by the GST-TbR-I Thr204Asp kinase (Figures 1A and 1B; see also Figure S1A available online). The library we used represented 1 3 10 6 independent clones of human cDNA, which were screened. Phosphorylation of clones in our primary screen was a rare event, i.e., an average of 9 positive clones per single plate expressing an average of 1000 plaques, and 9 large plates were used in the primary screen. Secondary screens with selected positive clones from the primary screen were required to confirm specific (A) The sequence of the insert in clones containing protein that was phosphorylated by the TbR-I construct is shown (human eEF1A1; NCBI accession number NM_001402.5). The upper panel shows the nucleotide sequence of the insert, with the start atg (Met1) and the stop tga codons indicated. Sequences that were used for NCBI BLAST search are underlined. The lower panel shows amino acid sequence of identified eEF1A1. Domain I is indicated by a single line, domain II by a double line, and domain III by a dashed line. (B) Purified GST-eEF1A1 is strongly phosphorylated in vitro upon incubation with purified GST-TbR-I Thr204Asp construct (GST-TbR-I). The upper panel shows incorporation of 32 P in proteins; the lower panel shows the same gel stained with Coomassie brilliant blue (CBB). (C) GST-eEF1A1 incubated without (left) or with (middle) the TbR-I construct was subjected to two-dimensional phosphopeptide mapping. The main phosphorylation site in eEF1A1 is indicated by the open arrowhead. The image at right shows that the synthetic eEF1A1 peptide Ser291-Lys313 containing phosphorylated Ser300 migrates at the same position (indicated by the open arrowhead) as the main phosphopeptides in GST-eEF1A1. Application points of tryptic digests and the peptide are indicated by black arrowheads. (D) TbR-I phosphorylates eEF1A1 at Ser300. GST-eEF1A1 constructs with Ser300Glu (SE) or Ser300Ala (SA) and wild-type construct (WT) were phosphorylated in vitro by TbR-I. Incorporated radioactivity is shown in the image. Arrows indicate migration positions of eEF1A1 and TbR-I constructs. As a control, TbR-I was used without addition of an eEF1A1 construct (No). Quantification of 32 P incorporation in GST-eEF1A1 and GST-TbR-I is shown below the image. See also Figure S1B for the image at shorter exposure. (E) Wild-type (left) and Ser300Ala (SA, right) eEF1A1 proteins phosphorylated in vitro by TbR-I were subjected to two-dimensional phosphopeptide mapping. Migration position of the Ser300-phosphorylated peptide is indicated by the open arrowhead. (F) Phosphorylation of the Ser300-containing peptide in cells treated with TGF-b1. Mv1Lu cells were transfected with HA-eEF1A1, metabolically labeled with [ 32 P]orthophosphate, and treated without (left) or with (right) TGF-b1. Two-dimensional phosphopeptide maps of immunoprecipitated eEF1A1 are shown. Migration positions of Ser300-containing phosphopeptides are indicated by open arrowheads and sample application points are indicated by black arrowheads in (E) and (F). Directions of electrophoresis (from 2 to +) and chromatography are indicated by arrows in left images and apply to all images in (C), (E), and (F). phosphorylation of expressed proteins by GST-TbR-I kinase, and 16 clones from the primary screen were found to express unique substrates of GST-TbR-I kinase (data not shown). The in vitro kinase assay was performed under conditions in which the specificity of the kinase was preserved [16, 17] . One of the identified clones corresponded to human eEF1A1 ( Figure 1A ; NCBI accession number NM_001402.5). Secondary screens confirmed that GST-TbR-I Thr204Asp phosphorylated a protein which was expressed by eEF1A1-containing clones (data not shown).
eEF1A1 Is Phosphorylated at Ser300 by TbR-I To validate the phosphorylation of eEF1A1 by TbR-I, we performed phosphorylation assays with purified eEF1A1, with eEF1A1 ectopically expressed in mammalian cells, and with endogenous eEF1A1 (Figure 1; Figure 2 ). We found that GST-TbR-I Thr204Asp phosphorylated purified GST-eEF1A1 in vitro (Figures 1B and 1C ; Figures S1B-S1D). Twodimensional phosphopeptide mapping of phosphorylated GST-eEF1A1 showed TbR-I-dependent appearance of three phosphopeptides with different intensities of phosphorylation; one of the phosphopeptides strongly dominated and two phosphopeptides were much weaker, as shown by incorporation of 32 P ( Figure 1C ). The major phosphopeptide was subjected to phosphoamino acid analysis to determine which amino acid was modified. We found that the serine residue was phosphorylated in this peptide, whereas no phosphothreonine or phosphotyrosine was detected ( Figure S1E ). Edman degradation-based sequencing of the peptide showed that the radioactive residue was located at the tenth position from the N terminus ( Figure S1F ). A serine residue at the tenth position was found only in the tryptic peptide Ser291-Lys313, as predicted by theoretical cleavage of eEF1A1 with trypsin (Figures S1E and S1F; data not shown). Moreover, the migration position of a synthetic eEF1A1 peptide Ser291-Lys313 containing phosphorylated Ser300 was identical to the migration position of 32 P-phosphorylated tryptic peptides from eEF1A1 ( Figure 1C ). Thus, GST-TbR-I Thr204Asp phosphorylates eEF1A1 in vitro at Ser300.
To confirm that Ser300 is the site of TbR-I-dependent phosphorylation, we generated eEF1A1 mutants with the Ser300 residue substituted by alanine, aspartic acid, or glutamic acid residues; purified them as GST-fusion proteins; and subjected them to phosphorylation by purified TbR-I kinase ( Figure 1D ). We found that mutations of Ser300 strongly decreased the phosphorylation of GST-eEF1A1 by GST-TbR-I Thr204Asp ( Figure 1D ). Two-dimensional phosphopeptide mapping showed that the major phosphopeptide did not appear on the maps of the Ser300Ala mutant of GST-eEF1A1, whereas it was present on the map of the wild-type protein ( Figure 1E ). This confirmed that Ser300 in eEF1A1 is the main site of direct phosphorylation by TbR-I in vitro.
To validate TbR-I-dependent phosphorylation of eEF1A1 in mammalian cells, we explored phosphorylation of transfected eEF1A1. We used two different constructs of eEF1A1, GFP-eEF1A1 and HA-eEF1A1, to exclude a possible interference of a particular tag; appearance of Ser300 phosphopeptide would suggest that the tag did not influence phosphorylation of eEF1A1. HA-tagged eEF1A1 (HA-eEF1A1), which was expressed in Mv1Lu cells metabolically labeled with [ 32 P]orthophosphate, showed appearance of a phosphopeptide at the same migration position as the phosphoSer300-containing peptide. Phosphorylation of this peptide was strongly enhanced upon treatment of cells with TGF-b1 ( Figure 1F ). Presence of GFP did not interfere with Ser300 phosphorylation by TbR-I, because GFP-eEF1A1 cotransfected with wild-type TbR-I contained a phosphopeptide that migrated at the same position as the phospho-Ser300-containing peptide ( Figure S1D ). Thus, results of the assays with eEF1A1 expressed in mammalian cells confirmed TbR-Idependent phosphorylation of eEF1A1 at Ser300.
To monitor phosphorylation of Ser300 in endogenous eEF1A1, we generated an antibody specific to phosphorylated Ser300 that does not recognize a nonphosphorylated protein ( Figure 2A ). This antibody did not recognize the Ser300Ala mutant of eEF1A1, whereas it detected wild-type eEF1A1 efficiently (Figure 2A) . Immunoblotting of the wholecell extracts with the pS300 antibody showed that TGF-b1 induced phosphorylation at Ser300 ( Figure 2B ). To confirm this finding, we performed immunoprecipitation of eEF1A1 with pS300 antibody and then immunoblotted with anti-eEF1A antibody ( Figure 2C ). The appearance of the eEF1A1 band recognized by pS300 antibody was observed after incubation of MCF-7 cells with TGF-b1 ( Figure 2C ). Comparison of pS300 and anti-eEF1A antibodies showed that both efficiently recognized eEF1A1 in an immunoprecipitation assay ( Figure S2A ). We observed that TGF-b1 did not affect expression of the endogenous eEF1A1 ( Figures 2B and 2D ). Immunoprecipitation of endogenous eEF1A1 from 32 P metabolically labeled MCF-7 cells showed that TGF-b1 induced phosphorylation of eEF1A1 ( Figure 2D ). The dynamics of the phosphorylation of 32 P-labeled eEF1A1 were similar to the dynamics of the phosphorylation of Ser300 in eEF1A1 monitored with the pS300 antibody ( Figures 2C and 2D) . Ratio of the Ser300-phosphorylated eEF1A1 was estimated to be up to 24% of the total eEF1A1 detectable in MCF-7 cells ( Figure S2B ). An interaction of eEF1A1 and TbR-I was observed, although the complex formation was weak, as expected for a substrateenzyme interaction ( Figure S2C ). Quantification of phosphorylation at Ser300 showed TGF-b-dependent stimulation to be 4-to 6-fold, as measured in different assays ( Figures  2A-2D ).
To confirm further that TbR-I was the kinase that phosphorylated eEF1A1 at Ser300, we cotransfected wild-type, constitutively active, and kinase-inactive constructs of TbR-I with eEF1A1; subjected cells to treatment with the TbR-I kinase inhibitor SB431542 and TGF-b1; and monitored phosphorylation of Ser300 ( Figure 2E ). We observed TGF-b1-dependent phosphorylation of eEF1A1 upon cotransfection of wild-type TbR-I, strong phosphorylation upon cotransfection of constitutively active TbR-I, and no phosphorylation upon cotransfection of kinase-inactive TbR-I. SB431542 strongly inhibited Ser300 phosphorylation ( Figure 2E ), further corroborating the involvement of TbR-I in phosphorylation of eEF1A1.
To confirm that TbR-I is required for phosphorylation of endogenous eEF1A1 at Ser300 in cells, we explored eEF1A1 phosphorylation in Mv1Lu cells and in R4.2 cells, which are deficient for TbR-I ( Figure 2F ). We observed that TGF-b1 and the TbR-I inhibitor SB431542 did not have an effect on phosphorylation of eEF1A1 in the assays with R4.2 cells. In contrary, in parental Mv1Lu cells that express functional TbR-I, TGF-b1 enhanced eEF1A1 phosphorylation at Ser300, which was inhibited by SB431542 ( Figure 2F ). The inhibition of TbR-I kinase led also to the inhibition of TGF-b1-dependent phosphorylation of endogenous eEF1A1 in COS-7 cells ( Figure 2G ) and MCF-7 cells ( Figure S2D ). Thus, the assays with cultured cells (Figure 2 ) suggest that TbR-I is the kinase that phosphorylates eEF1A1 at Ser300 in vivo.
Ser300 Is Important for the Efficient Binding of AminoacyltRNA to eEF1A1, and Ser300 Phosphorylation Inhibits Protein Synthesis The role of eEF1A1 in translation is to deliver the tRNA-amino acid complex to the elongating protein chain. This requires the binding of aminoacyl-tRNA (aa-tRNA) to eEF1A1, the GTPase activity of eEF1A1, and the exchange of GDP to GTP for another cycle of protein chain synthesis [18, 19] . Ser300 is located in domain II of eEF1A1, which provides sites of interaction with aa-tRNA [20] [21] [22] (Figure S3A ). This suggests that the (A) pS300 antibody recognizes phosphorylated Ser300 in eEF1A1. Wild-type (WT) and Ser300Ala mutant (S300A) GST-eEF1A1 were incubated in vitro with TbR-I Thr204Asp construct as indicated. Phosphorylation of wild-type eEF1A1 was recognized by immunoblotting with pS300 antibodies (upper panel). The lower panel shows loading control for GST-eEF1A1. (B and C) Endogenous eEF1A1 is phosphorylated at Ser300 upon treatment of cells with TGF-b1. Phosphorylation of endogenous eEF1A1 in MCF-7 cells was monitored by immunoblotting of whole-cell extract (WCE) with pS300 antibody (B). Phosphorylation was also monitored by immunoprecipitation with pS300 antibody followed by immunoblotting with anti-eEF1A1 antibody (C). MCF-7 cells were treated as indicated. Quantification of eEF1A1-specific signals is shown in arbitrary units at top of panels. (D) 32 P incorporation in eEF1A1 is enhanced upon TGF-b1 treatment. MCF-7 cells were metabolically labeled with [ 32 P]orthophosphate and treated with TGF-b1 as indicated. Immunoprecipitated eEF1A1 was detected with specific antibodies (lower panel) and exposed in a phosphorimager (upper panel). Quantification of 32 P incorporated in eEF1A1 is shown at top of upper panel. (E) Kinase activity of TbR-I is required for phosphorylation of eEF1A1 at Ser300. COS-7 cells were cotransfected with wild-type (WT), constitutively active (CA), and kinase-inactive (KD) TbR-I and wild-type eEF1A1 and were treated with TGF-b1 and/or SB431542 as indicated. Phosphorylation of Ser300 was monitored by immunoblotting with pS300 antibody (upper panel). Middle and lower panels show expression of HA-tagged TbR-I and eEF1A1 constructs; in the middle panel, TbR-I constructs were migrating immediately above the eEF1A1. Quantification of eEF1A1 Ser300 phosphorylation is shown in arbitrary units at top of upper panel; in the unlabeled lanes, signals were lower than 2.0 arbitrary units. (F) Endogenous eEF1A1 is not phosphorylated in TbR-I-deficient R4.2 cells but is phosphorylated in parental Mv1Lu cells. Endogenous eEF1A1 was immunoprecipitated with anti-eEF1A1 antibody from cells treated with TGF-b1 and the TbR-I kinase inhibitor SB415432 as indicated (upper panel). Phosphorylation of Ser300 was monitored by immunoblotting with pS300 antibody. Loading controls for eEF1A1 and actin are shown. TGF-b-dependent phosphorylation of Smad2 (pS2) and expression of Smad2 (Smad2) are indicated. Quantification of pS300 signal is shown at top in arbitrary units. (G) The TbR-I kinase inhibitor SB415432 inhibits TGF-b1-dependent phosphorylation of endogenous eEF1A1 at Ser300. COS-7 cells were transfected with wild-type TbR-I (HA-TbR-I) and treated with TGF-b1 and/or SB415432 as indicated. Endogenous eEF1A1 was immunoprecipitated with anti-eEF1A1 antibody (eEF1A1) and probed with pS300 antibody (pS300, upper panel). Loading control for eEF1A1 is shown in the middle panel. Expression of HA-TbR-I was monitored by immunoblotting of whole-cell extract (WCE) with anti-HA antibodies (HA) and is shown in the lower panel. Migration positions of eEF1A1 and HA-TbR-I constructs, IgG, and a nonspecific band (Bg) are indicated by arrows.
introduction of a bulky and strongly charged phosphoryl group at Ser300 might interfere with binding of aa-tRNA to eEF1A1. Thus, we explored whether aa-tRNA binding to eEF1A1 would be affected by changes of properties at the Ser300 site. We found that Ser300Glu and Ser300Asp mutants bound aa-tRNA inefficiently and that the Ser300Ala mutant had weaker binding of aa-tRNA as compared to the wild-type ( Figure 3A ; efficiency of binding 48.3% for wild-type, 38.0% for Ser300Ala, and 12.2% for Ser300Glu mutants; see Experimental Procedures). When the binding of aa-tRNA to the wild-type eEF1A1 was taken as 100%, the Ser300Ala mutant bound 82% of aa-tRNA. This indicates an importance of a hydroxyl group of Ser300 in nonphosphorylated eEF1A1 for binding of aa-tRNA. Analysis of the 3D structure of the elongation factor in complex with aa-tRNA showed that Ser300 is located in the region that interacts with the 3 0 end of aa-tRNA. Notably, residues corresponding to Glu293, His295, His296, and Asn307 in human eEF1A1 form hydrogen bonds with aa-tRNA [21] . Thus, the 2OH group of Ser300 may be involved in formation of the aa-tRNA-interacting surface, and removal of this group may prevent an efficient interaction of eEFA1 and aa-tRNA. This indicates that the Ser300Ala mutant may have a negative effect on eEF1A1 function in protein synthesis as compared to the wild-type protein. Mimicking phosphorylation of Ser300 by introducing a negative charge at this site diminished aa-tRNA binding, as was expected from the location of Ser300 in domain II of eEF1A1 ( Figure 3A ; Figure S3A ). To explore whether mutations of Ser300 can affect protein synthesis, we added purified GST-fusion constructs of eEF1A1 to an in vitro translation reaction ( Figure 3B ). We observed that wild-type eEF1A1 enhanced the rate of protein synthesis, whereas the Ser300Ala mutant had a slightly weaker effect and the Ser300Asp mutant was essentially inactive. These effects on protein synthesis correlated with the impact of the mutations on aa-tRNA binding. We did not observe any significant differences in GDP/GTP binding by the Ser300 mutants as compared to wild-type eEF1A1 (data not shown). This indicates that Ser300 contributes to binding of aa-tRNA and protein synthesis in vitro and that phosphorylation at Ser300 inhibits efficient aa-tRNA binding by eEF1A1.
To explore whether TbR-I can affect translation reactions directly, we added purified GST-TbR-I Thr204Asp, which has a constitutively active kinase, to an in vitro translation reaction. We found that increased quantities of GST-TbR-I Thr204Asp inhibited in vitro synthesis of luciferase, which was used as a template ( Figure 3C) . Addition of the TbR-I kinase inhibitor SB431542 prevented inhibition of mRNA translation, suggesting that the kinase activity of TbR-I was essential for the inhibitory effect ( Figure 3C ). We also observed that the addition of GST-TbR-I Thr204Asp to the in vitro translation mixture led to phosphorylation of eEF1A1 at Ser300 ( Figure 3D ). Type II TGF-b and BMP receptors did not inhibit protein synthesis ( Figure 3E) ; note that type II receptors are considered to have constitutively active kinases [1] [2] [3] . Another type I TGF-b-family receptor, ALK6, also did not affect protein synthesis ( Figure 3F ; see Figures S3B-S3D for controls of GST constructs). Thus, our data suggest that TbR-I kinase affects protein synthesis, which correlates with phosphorylation of eEF1A1 at Ser300.
To explore the potential impact of Ser300 phosphorylation on protein synthesis in intact cells, we generated stably transfected MCF-7 human breast epithelial cells expressing wildtype, Ser300Ala, or Ser300Glu mutants of eEF1A1 ( Figure 4A ). The level of Cd 2+ -induced expression for transfected constructs was from 25% to 50% of the level of endogenous eEF1A1 in various experiments. With stably transfected MCF-7 cells, we found that the rate of protein synthesis increased upon transfection of wild-type eEF1A1 as compared to empty vector-transfected cells ( Figure 4B ). TGF-b1 inhibited protein synthesis in both empty vector-and wild-type-transfected cells. Expression of the Ser300Ala mutant resulted in a lower rate of 35 S incorporation as compared to vector-transfected cells, and in abrogation of the TGF-b1 effect. An even lower rate of protein synthesis was observed in cells expressing the Ser300Glu mutant, without a significant impact of the TGF-b1 treatment ( Figure 4B ). These results are in agreement with Ser300Ala and Ser300Glu being less efficient binders of aa-tRNA, although to a different degree, as compared to the wild-type protein ( Figure 3A) . The same effects of Ser300 mutations on the protein synthesis and its TGF-b-dependent inhibition were observed upon different lengths of incubation of cells with TGF-b ( Figures S4A and S4B ). The effect of Ser300 mutations was dependent on the expression level of the mutants in cells, because some TGF-b responsiveness was observed with the lower levels of expression (data not shown). Protein synthesis was evaluated by measuring incorporation of [ S]cysteine in proteins was measured after protein separation in SDS-polyacrylamide gel electrophoresis (data not shown). Our attempts to express eEF1A1 constructs and then knock out endogenous eEF1A1 with specific small interfering RNA showed that the decrease in expression of eEF1A1 led to cell death in control cells; the response of cells transfected with wild-type or mutant eEF1A1 was similar to the observed responses of stably transfected cells (Figures S4C-S4E ). This is in agreement with phosphorylation at Ser300 being an important component in TGF-b-dependent inhibition of protein synthesis.
Modification of Ser300 in eEF1A1 Inhibits Cell Proliferation
Enhanced expression of eEF1A factors has been observed in breast, colorectal, and prostate cancers [9, 15, [23] [24] [25] . This correlates with the enhanced proliferation of malignant cells. To explore the potential impact of eEF1A1 phosphorylation at Ser300 on cells, we studied proliferation of cells stably transfected with various constructs of eEF1A1 ( Figure 4A ; Figure 5 ). We studied [ 3 H]thymidine incorporation and substrate-dependent and anchorage-independent growth of cells ( Figure 5 ). The use of different proliferation assays ensured strength of conclusions. For the wild-type and Ser300 mutants of eEF1A1, we observed a correlation of the cell proliferation responses ( Figure 5 ) with protein synthesis (Figure 3 ; Figure 4 ) and aa-tRNA binding ( Figure 3A) . Notably, Ser300Ala and Ser300Glu mutants had an inhibitory effect on proliferation and did not show a significant TGF-b-inhibitory response in the [ 3 H]thymidine incorporation assay, whereas expression of wild-type eEF1A1 led to slightly enhanced proliferation with preserved TGF-b1 responsiveness ( Figure 5A ). This assay reflects regulation of DNA synthesis as a readout for cell proliferation during a 24 hr treatment with TGF-b1 ( Figure 5A ). When we evaluated cell growth, similar effects of eEF1A1 constructs were observed after treatment with TGF-b1 for 1 week (Figures 5B and 5C) . Notably, wild-type eEF1A1 enhanced cell proliferation and preserved the TGF-b1-inhibitory effect, whereas Ser300Ala and Ser300Glu mutants did not enhance cell proliferation and did not show TGF-b1-dependent inhibition (Figures 5B and 5C) . The Ser300Ala mutant even showed some enhancement in proliferation; TGF-b1-dependent stimulation has been observed for fibroblasts, probably as a result of TGF-b1 effect on the matrix formation [26] .
In mammospheres, Ser300 mutants of eEF1A1 inhibited cell growth as compared to wild-type eEF1A1 (Figures 5D and 5E ; Figures S5A and S5B ). In this anchorage-independent growth assay, cells preserved TGF-b responsiveness, although the relative responsiveness was much lower for the Ser300 mutants as compared to the wild-type eEF1A1-expressing cells. Thus, three different assays evaluating short-and longterm effects of eEF1A1 on cells cultured on substrate or in mammospheres suggest importance of Ser300 in eEF1A1 for TGF-b-dependent inhibition of cell proliferation. Further studies of Ser300's role in regulation of cell proliferation may provide additional insights into the details of the molecular mechanisms coupling TGF-b signaling, protein synthesis, and cell proliferation.
We observed that wild-type eEF1A1 and the Ser300Ala and Ser300Glu eEF1A1 mutants did not interfere with TGF-b1-dependent activation of CAGA(12)-luc reporter ( Figure S5C ). We observed also that the eEF1A1 constructs, upon expression in MCF-7 cells, had no impact on TGF-b-dependent cell death, migration, or invasiveness (data not shown).
Taken together, our data indicate that Ser300 phosphorylation of eEF1A1 is a novel mechanism of TGF-b-dependent regulation of cell proliferation.
Phosphorylation of eEF1A1 at Ser300 Is Decreased in Human Breast Carcinomas Because TGF-b is involved in tumorigenesis, we explored the status of eEF1A1 phosphorylation at Ser300 in tumors and normal tissues of human breast ( Figure 6 ). We performed staining of tissue microarrays of 45 human breast cancer samples and noncancerous specimens with a pS300 antibody that specifically recognizes phosphorylated Ser300 and with an antibody to wild-type eEF1A as a control for eEF1A1 expression. We observed that tumor cells had significantly decreased pS300 staining, whereas ductal epithelial cells in noncancerous specimens showed positive staining ( Figures  6A-6D) . Notably, no detectable phosphorylation at Ser300 was observed in malignant cells of all 30 tested infiltrating ductal carcinomas ( Figures 6A-6D and 6G ), in 6 of 8 cases of papillary carcinomas, or in all 3 tested cases of infiltrating lobular carcinomas (data not shown). We also observed significant increase in pS300 staining in stromal cells of tumors as compared to stromal cells in noncancerous cases (Figure 6 ). Phosphorylation at Ser300 was observed in normal epithelial cells in four tested noncancerous cases. Staining with antieEF1A antibody showed expression of the protein in all tested cancer and normal cases ( Figures 6E and 6F ). Our observations are in agreement with the notion of increased expression of TGF-b in tumors but decreased sensitivity to TGF-b in transformed tumor cells [1] [2] [3] . Increased expression of TGF-b also leads to enhanced TGF-b signaling in nonmalignant cells [1] [2] [3] . Decreased antiproliferative TGF-b signaling in malignant cells may be the result of impaired phosphorylation of TbR-I substrates, with eEF1A1 being an example of such a substrate. Decreased phosphorylation at Ser300 was also observed in proliferating cultured human breast carcinoma cells as compared to TGF-b1-treated and proliferation-inhibited cells. This supports the correlation between the high proliferation rate and the low level of Ser300 phosphorylation ( Figure 6H ). Thus, our observations indicate that phosphorylation of Ser300 may be altered in human breast cancer, i.e., decreased in malignant tumor cells as compared to in normal epithelial cells.
Discussion
In this study, we showed that the phosphorylation of eEF1A1 at Ser300 by TbR-I is a mechanism of a direct inhibitory effect of TGF-b on protein synthesis that correlates with TGF-b-dependent inhibition of cell proliferation (Figures 2-5) . We found that the phosphorylation of Ser300 is also altered in human breast cancer ( Figure 6 ). Enhanced expression of eEF1A was observed in human cancers, without discriminating its isoforms 1 and 2, and eEF1A was found to promote carcinogenic transformation of epithelial cells and fibroblasts [24, [27] [28] [29] [30] [31] . eEF1A is highly expressed in metastatic cell lines [ and alterations of eEF1A expression correlate with metastatic potential of mammary adenocarcinoma [32] . A truncated form of eEF1A was identified as the PTI-1 oncogene in human cancer [33] . In PTI-1, the amino acid residue corresponding to Ser300 is substituted by Gly [34] . Altogether, these reports indicate that eEF1A1 is an important regulator of tumorigenesis. TGF-b signaling also has a strong impact on tumorigenesis [1] [2] [3] . Our results show that eEF1A1 is a convergence point of TGF-b signaling and regulation of protein synthesis, with the direct phosphorylation of eEF1A1 by TbR-I as a triggering mechanism of this crosstalk.
eEF1A1 has a number of functions in mammalian cells [35] . Location of Ser300 in domain II of eEF1A pointed to the possible interference of Ser300 phosphorylation with aa-tRNA binding, which was confirmed experimentally (Figure 3 ; Figures S3A and S3B ). This is in agreement with the potent growth-inhibitory activity of TGF-b and may be the mechanism that prepares cells for the lower rate of proliferation by inhibiting protein synthesis. Our observations indicate that TGF-b has an impact on protein synthesis via targeting eEF1A1 (Figure 3; Figure 4 ). This pathway does not require transcriptional activation of genes and may function in cooperation with the other pathways of TGF-b, e.g., the Smad-dependent pathway [1] [2] [3] . An indirect effect of TGF-b on the cell cycle via activation of dephosphorylation of p70 S6K in EpH4 cells has been reported [14] , although in smooth muscle cells, TGF-b had no effect on p70 S6K activity [36] . An involvement of the mTOR pathway in TGF-b-dependent regulation of cell size, and therefore protein synthesis, via S6K1 and eIF4E-binding protein 1 has also been reported [13] . Two proteins known to be involved in protein synthesis, TRIP-1 (a component of the eIF3 complex) and eIF2a, have also been reported as modulators of TGF-b signaling, but not in the context of regulation of mRNA translation [10] [11] [12] . Multiplicity of TGF-binitiated pathways is a feature that ensures robustness of TGF-b action. Smad2 and Smad3 phosphorylation by TbR-I is observed as early as after 20 min of treatment with TGF-b, followed by initiation of transcriptional responses [1] [2] [3] . eEF1A1 phosphorylation at Ser300 contributes to the inhibition of cell proliferation predominantly at the late stage of TGF-b action, after 4 to 6 hr of cell treatment with TGF-b ( Figure 5 ). Decreased Ser300 phosphorylation in human breast cancer indicates that this mechanism may be implicated in tumorigenesis, because decreased phosphorylation at Ser300 correlates with the higher proliferation rate of cells ( Figure 6 ). Thus, identification of eEF1A1 as a substrate of TbR-I unveils a novel translation-related regulatory pathway downstream of TbR-I.
Experimental Procedures
See Supplemental Experimental Procedures for detailed descriptions.
Cells and Constructs
GST-TbR-I Thr204Asp, GST-ALK6, GST-TbR-II, and GST-BMPR-II (all human) constructs and properties of the purified receptor kinase were described previously [16] . GST-eEF1A1 construct functional activity was confirmed in aa-tRNA binding, GTPase activity, and GDP/GTP binding assays. pHA-EF1A (human) and pGST-EF1A (bovine) were obtained from Ruben Donis (University of Nebraska-Lincoln, USA), and pGL-EF1A for rat EF1A1-GFP was obtained from Gang Liu [35] . Site-directed mutagenesis was performed with a QuikChange Site-Directed Mutagenesis Kit (Stratagene), and all constructs were verified by DNA sequencing. For the generation of stably transfected MCF-7 cells, human eEF1A1 constructs were cloned into a pMEP4 vector (Invitrogen). Immunoblotting with pS300, eEF1A1, anti-pRb (pRb), anti-phospho-Ser780 pRb (ppRb), and anti-actin antibodies is shown. Equal loading was monitored with anti-actin antibody.
Screening of cDNA Library for TbR-I Substrates A human fetal lung lgt11 cDNA library (titer 5.7 3 10 10 plaque-forming units/ml, estimated representation of not less than 1 3 10 6 independent clones; Clontech) was screened as described by Fukunaga and Hunter [37] .
Generation of pS300 Antibodies A rabbit antiserum recognizing phosphorylated Ser300 in eEF1A, pS300, was raised against a synthetic peptide corresponding to amino acid residues 295-305 in the human eEF1A1 sequence (HHEALpSEALPG; pS indicates phosphorylated serine residue) (KLH; Calbiochem). The antibodies were affinity purified by passing the antiserum over three consecutive columns of immobilized nonphosphorylated peptide, phosphoserineagarose, and phosphorylated peptide.
In Vitro Phosphorylation Assay, [ orthophosphate labeling, and tryptic phosphopeptide mapping were carried out as described previously [16] . For experiments with a synthetic peptide, SVEMHHEALpSEALPGDNVGFNVK peptide (pS indicates phosphorylated Ser300) was synthesized by PeptideSynthetics Ltd. (Fareham, UK).
aa-tRNA Binding Assay
Radioactively labeled aa-tRNA was synthesized for 30 min at 37 C in a reaction containing buffer components and 10 U/ml total bovine liver tRNA (Sigma), 10 mCi/ml [ 14 C]leucine, and 250 mg/ml aa-tRNA synthetase (Sigma). Efficiency of aminoacylation under the conditions used was found to be more than 80% as evaluated by the incorporation of [ 14 C]leucine in aa-tRNA. Observed binding of [
14 C]leucine-tRNA to the eEF1A1 wild-type construct indicated that 48.3% of the eEF1A1 protein preparation bound aa-tRNA; the binding efficiency was 38.0% for the Ser300Ala mutant and 12.2% for the Ser300Glu mutant.
In Vitro Translation Assay
The effect of TbR-I and other receptors on translation was studied using a TNT Quick Coupled Transcription/Translation System (Promega). Indicated amounts of GST constructs in 4 ml aliquots were added to 21 ml of translation mixture. GST constructs of eEF1A1 were added in 1 mg aliquots of proteins to 25 ml of translation mixture.
Metabolic Labeling
Stable clones of MCF-7 cells were seeded into 24-well plates. Thereafter, the cells were cultured for 24 hr and then treated with 10 ng/ml of TGF-b1 (PeproTech EC) for another 24 hr. For the last 2 hr, the cells were incubated in cysteine-and methionine-free MCDB 104 medium in the presence of 1 mCi/ml Redivue Pro-Mix (GE Healthcare/Amersham Pharmacia Biotech), and radioactivity incorporated into proteins was measured.
Cell Proliferation Assays
Stably transfected MCF-7 cells expressing empty pMEP4 vector or wildtype or Ser300 mutants of HA-eEF1A1 and cultured in presence of 5 mM CdCl 2 were plated in 12-well plates (Sarstedt) (10 4 cells per well). After 24 hr, the medium was changed to Dulbecco's modified Eagle's medium with 3% fetal bovine serum and 5 mM CdCl 2 , and cells were cultured as indicated in descriptions of experiments. Medium was changed three times per week. After incubation, cells were washed, fixed, and stained. Plates were scanned and cell proliferation was evaluated by measuring cell mass and staining in wells with ImageJ 1.40g software (http://rsbweb.nih.gov/ij/). For the [ 3 H]thymidine incorporation assay, cells were prepared as described above. Incorporation of [ 3 H]thymidine (1 mCi/ml) was performed during the last 2 hr of TGF-b1 treatment as described previously [16] .
Anchorage-Independent Growth Assay
The same number of cells for each construct (vector, wild-type, and Ser300 mutants) were seeded in six-well plates on an agarose layer. Cells were cultured for 2 weeks with or without TGF-b1 (5.0 ng/ml). After 2 weeks, mammospheres were collected and plated in six-well plates. After attachment of mammospheres for 6 hr, cells were washed with medium, and fresh medium was added. After culturing for a further 24 hr, cells were washed and fixed, and quantification of attached spheroids was performed with ImageJ software.
Immunohistochemistry
AccuMax breast cancer arrays were used (ISU ABXIS Co., Ltd.). Each array slide contained 45 cases of cancer tissues and four nonneoplastic tissues. Arrays were stained with pS300, eEF1A (anti-EF-Tu antibody; Santa Cruz Biotechnology), and anti-phospho-Smad2 (pS2) antibodies. The specificity of the pS300 antibody was evaluated as shown in Figure 2 and Figure S6 . Slides were stained with VECTASTAIN Elite ABC kits (Vector Laboratories) and counterstained with hematoxylin. Stained tissues were photographed with a Leica DFC camera, and images were acquired with Leica QWin Standard software (Leica Microsystems Imaging Solutions Ltd.).
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